文献速递呼吸危重症与机械通气

顺阿曲库铵与维库溴铵在急性呼吸窘迫综合征患者中的疗效观察性研究

An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

本研究利用全国代表性数据库,纳入ICU内诊断为ARDS或存在ARDS危险因素、接受机械通气并连续输注神经肌肉阻滞剂至少2天的患者,经倾向性匹配比较顺阿曲库铵与维库溴铵的结局。匹配后共3802例(每组1901例),两组死亡率无显著差异(OR 0.932;P=0.40),但顺阿曲库铵组机械通气天数(-1.01天;P=0.005)和ICU天数(-0.98天;P=0.028)更少,出院回家可能性两组相当(OR 1.19;P=0.056)。

要点

  • 顺阿曲库铵与维库溴铵相比,ARDS患者住院死亡率无显著差异。
  • 顺阿曲库铵组机械通气天数减少约1天,ICU天数减少约1天。
  • 两组出院回家可能性无显著差异(P=0.056)。

核心结论

  • 与维库溴铵相比,顺阿曲库铵未显著改善ARDS患者住院死亡率,但改善了机械通气天数和ICU天数等其他临床重要结局。

研究设计与样本

  • 基于全国代表性数据库的观察性研究,纳入ICU内诊断为ARDS或存在ARDS危险因素、接受机械通气并连续输注神经肌肉阻滞剂至少2天的患者。
  • 采用倾向性匹配平衡患者和医院因素,匹配后共3802例,顺阿曲库铵组和维库溴铵组各1901例。

主要发现

  • 匹配后两组住院死亡率无显著差异(OR 0.932;P=0.40)。
  • 顺阿曲库铵组机械通气天数较维库溴铵组减少1.01天(P=0.005)。
  • 顺阿曲库铵组ICU天数较维库溴铵组减少0.98天(P=0.028)。
  • 两组出院回家可能性无显著差异(OR 1.19;P=0.056)。
  • 两组住院天数无显著差异(-0.66天;P=0.411)。

临床怎么用

  • 对于存在ARDS风险或已发生ARDS且需要连续输注神经肌肉阻滞剂的患者,顺阿曲库铵可作为优先选择的神经肌肉阻滞剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: The neuromuscular blocking agent cisatracurium may improve mortality for patients with moderate-to-severe acute respiratory distress syndrome (ARDS). Other neuromuscular blocking agents, such as vecuronium, are commonly used and have different mechanisms of action, side effects, cost, and availability in the setting of drug shortages. OBJECTIVES: To determine whether cisatracurium is associated with improved outcomes when compared with vecuronium in patients at risk for and with ARDS. METHODS: Using a nationally representative database, patients who were admitted to the ICU with a diagnosis of ARDS or an ARDS risk factor, received mechanical ventilation, and were treated with a continuous infusion of neuromuscular blocking agent for at least 2 days within 2 days of hospital admission were included. Patients were stratified into two groups: those who received cisatracurium or vecuronium. Propensity matching was used to balance both patient- and hospital-specific factors. Outcomes included hospital mortality, duration of mechanical ventilation, ICU and hospital duration, and discharge location. MEASUREMENTS AND MAIN RESULTS: Propensity matching successfully balanced all covariates for 3,802 patients (1,901 per group). There was no significant difference in mortality (odds ratio, 0.932; P = 0.40) or hospital days (-0.66 d; P = 0.411) between groups. However, patients treated with cisatracurium had fewer ventilator days (-1.01 d; P = 0.005) and ICU days (-0.98 d; P = 0.028) but were equally likely to be discharged home (odds ratio, 1.19; P = 0.056). CONCLUSIONS: When compared with vecuronium, cisatracurium was not associated with a difference in mortality but was associated with improvements in other clinically important outcomes. These data suggest that cisatracurium may be the preferred neuromuscular blocking agent for patients at risk for and with ARDS.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Sottile PD, Kiser TH, Burnham EL, et al. An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2018. PMID: 29241014. doi:10.1164/rccm.201706-1132OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。